PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer
The combination of nivolumab with ipilimumab has been proven to [...]
Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer
A recent study, published in Clinical Genitourinary Cancer reports a [...]
Patients may not be able to tolerate recommended dose of cabozantinib
A recent study published on Oncology this month suggests that [...]
Alternative sunitinib dosing schedule
A recent study carried out by a Japanese research team [...]
Alternative 2 weeks on/1 week off dosing schedule for sunitinib
The results from a phase 2 study looking at the [...]
European Medicines Agency approves 4-week dosing schedule for nivolumab
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Alternative sunitinib dosing schedule for the treatment of kidney cancer improves adverse events
Recently, the results of several studies have demonstrated that a [...]
